A Phase 3, Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physicians Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis

Trial Profile

A Phase 3, Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physicians Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis

Recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Jun 2017

At a glance

  • Drugs Dexamethasone (Primary) ; Ixazomib (Primary) ; Cyclophosphamide; Lenalidomide; Melphalan; Thalidomide
  • Indications Amyloidosis
  • Focus Registrational; Therapeutic Use
  • Acronyms TOURMALINE-AL1
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 22 Mar 2017 Planned End Date changed from 1 Apr 2020 to 1 Sep 2018.
    • 22 Mar 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Sep 2018.
    • 17 Dec 2015 Planned End Date changed from 1 Aug 2018 to 1 Aug 2020, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top